Matthew Brodsky is a Neurology physician affiliated with Oregon Health & Science University. OpenAlex indexes 71 publications with 5,250 citations (h-index 24); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3181 SW Sam Jackson Park Rd
Portland, OR 972393011
Telephone
503-494-7772Registry record last updated 8 Jul 2007.
Clinical trials
- Ultra High Field Magnetic Resonance Imaging as a Biomarker for Premotor Parkinson's Disease
Sponsor: Oregon Health and Science University
- Clinical Outcomes of Deep Brain Stimulator (DBS) Electrodes Placed Using Intraoperative Computed Tomography (CT) and Frameless Stereotaxis
Sponsor: Oregon Health and Science University
- Effects of a Dopamine Agonist on Pharmacodynamics of Levodopa in Parkinson's Disease
Sponsor: Oregon Health and Science University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ACADIA Pharmaceuticals IncProgram year202528 payments$32,606openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year202517 payments$11,537openpaymentsdata.cms.gov ↗
- Boston Scientific CorporationProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
96.8%Aromatic Amino Acid Decarboxylation Inhibitor51.8%Carbidopa-Levodopa55%Carbidopa-Levodopa Er27%Rytary17%Part D≥72 patientsCholinesterase Inhibitor12.3%Donepezil Hcl69%Rivastigmine31%Part D<11 patients+ 9 more classes in this area
Cardiovascular
1.9%Beta blocker1.9%Propranolol Hcl100%Part D<11 patientsMusculoskeletal
1.4%gamma-Aminobutyric Acid-ergic Agonist1.4%Baclofen100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Directional Deep Brain Stimulation for Parkinson's Disease: Results of an International Crossover Study With Randomized, Double-Blind Primary Endpoint
Neuromodulation Technology at the Neural Interface
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Orwoll, MD
Oregon Health & Science University
Aaron Caughey, MD
Oregon Health & Science University
Tomasz Beer, MD
Oregon Health & Science University
John Nutt, MD
Oregon Health & Science University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”